Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug pricing

No-deal Brexit likely to increase cost of new medicines, Scottish government says

Leaving the UK without a deal in place may also slow access to new medicines, the Scottish government has said.

Scottish government report no deal brexit NBSS19

Source: Nic Bunce / Shutterstock.com

The ‘Scottish government overview of no-deal preparations’, published on 8 October 2019, lists what the Scottish government sees as the potential impacts of a no-deal Brexit

The Scottish government has said it is “likely that the cost of new medicines in the UK will increase” under a no-deal Brexit.

The warning was made in a ‘Scottish government overview of no-deal preparations’, published on 8 October 2019. The document lists what the Scottish government sees as the potential impacts of a no-deal scenario and outlines plans to mitigate the impact of this scenario on Scotland.

It also says that changes to the UK medicines licensing process “may result in slower access to new medicines and medicine shortages”, and warns of “myriad impacts” to the NHS and social care in Scotland: particularly around supplies of medicines and medical devices, and on the workforce.

In a consideration of general no-deal Brexit impacts, the report warns of a “significant reduction” in both imports and exports, and says that the impact of this on Scotland could, potentially, be larger that the rest of the UK because of the nation’s geography.

Listing actions it has taken to mitigate impact, the report says the government has established a Scottish Medicines Shortage Response Group to “review evidence and intelligence, recommend action and instigate escalation to the UK Medicines Shortage Response Group”.

However, it adds that the quality of engagement between the UK and Scottish government “has deteriorated since the appointment of the current government in July [2019]”, and claims that Scottish ministers were invited to “only 8 out of over 50 meetings of the new [Exit Operations] Committee”. This, it says, is limiting that ability of both governments to effectively plan for no-deal.

It is, the report notes, “important to note that leaving the EU with a deal would also involve significant levels of hardship for Scotland”.

The Scottish report was released on the same day that that the UK government published its own ‘No-deal readiness report’, which argues that Brexit could lead to opportunities that “may include innovative regulation of novel advanced therapies and medicines, and a streamlined approach to clinical trial reporting and conduct”, supported by fast track visas for “world-leading scientists”.

The UK government is, its report says, introducing “light-touch processes” to allow businesses, including those in the medical sector, “to convert existing EU approvals into UK approvals”.

The UK report says that the government is continuing to work with the Scottish and Welsh governments and the Northern Ireland civil service to prepare for a potential no-deal Brexit.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207181

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.